Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

18.45 +0.01 (+0.05%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries ADR

< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >
71 Biggest Movers From Yesterday
Gainers Avis Budget Group, Inc. (NASDAQ: CAR) shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales... 
Via Benzinga
Election Day
Teva rose a whopping 8.34% today. 
Via Talk Markets
Earnings Scheduled For October 27, 2021
Companies Reporting Before The Bell • McDonald's (NYSE:MCD) is expected to report quarterly earnings at $2.46 per share on revenue of $6.03 billion. • General... 
Via Benzinga
Teva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,000,000,000 of Sustainability-Linked Senior Notes
From Teva Pharmaceutical Industries Limited
Via Business Wire
Why Teva Pharmaceutical Stock Is Jumping Today
The company won in a California opioid-related lawsuit. 
Via The Motley Fool
California Judge Rules For Drugmakers In Major Opioid Litigation
A California judge cleared four drugmakers of liability, accusing the companies of causing widespread opioid addiction in the state. Teva Pharmaceuticals Industries Ltd... 
Via Benzinga
24 Stocks Moving in Tuesday's Pre-Market Session
Gainers Baosheng Media Group Holdings Limited (NASDAQ: BAOS) rose 119% to $3.43 in pre-market trading after declining 3% on Monday. The company, last month, swung to a loss... 
Via Benzinga
California Judge Rules That Teva Did Not Cause a Public Nuisance or Make False or Misleading Statements About Opioids
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reports Encouraging Data From Late-Stage Schizophrenia Trial
Teva Pharmaceuticals Industries Ltd (NYSE: TEVA) announced results from the Phase 3 trial comparing TV-46000/mdc-IRM once monthly (q1m) and TV-46000/mdc-IRM once... 
Via Benzinga
New Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Time to Impending Relapse Compared to Placebo in Patients with Schizophrenia
From Teva Pharmaceutical Industries Limited
Via Business Wire
No Negative Reaction
Today the impact of the Delta variant hit US GDP which was only 2% annualized, vs estimates of 2.6%, based on Q3 data which came out today. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2021
Upgrades For Boot Barn Holdings Inc (NYSE: 
Via Benzinga
Teva Pharmaceutical Industries (TEVA) Q3 2021 Earnings Call Transcript
TEVA earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Teva Pharmaceutical Industries Fell Today
The pharmaceutical giant whiffs on both the top and bottom lines in its Q3. 
Via The Motley Fool
Looking Into Teva Pharmaceutical Indus's Return On Capital Employed
Pulled from Benzinga Pro data, Teva Pharmaceutical Indus (NYSE:TEVA) posted Q3 earnings of $623.00 million, an increase from Q2 of 7.04%. Sales dropped to $3.89 billion, a 0.59%... 
Via Benzinga
Teva Q3 Earnings Fall Short Of Expectations; Reaffirms FY21 Guidance
Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) Q3 sales reached $3.89 billion, shrinking 2% Y/Y or 3% in local currency terms, missing the consensus of $4.03... 
Via Benzinga
Teva Stock Dips As The Sales Downfall Continues For Its Biggest Product
Teva's multiple sclerosis treatment, Copaxone, is facing generic competition. 
Via Investor's Business Daily
Teva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reports Third Quarter 2021 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tuesday Market Coverage
Thermo Electron fell on the publication of its social responsibility report today. 
Via Talk Markets
Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021
From Teva Pharmaceutical Industries Limited
Via Business Wire
Wednesday Market Coverage
Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal. 
Via Talk Markets
Bitcoin Futures Arrive
Today you can finally hold Bitcoins via an exchange-traded fund. 
Via Talk Markets
Is This The Most Exciting Medical Breakthrough Of The Decade
FN Media Group Presents Oilprice.com Market Commentary London – October 19, 2021 – According to Google’s Health boss David Feinberg… over one billion people a day search Google for health concerns.... 
Via FinancialNewsMedia
Chinese Growth Level
The hot news today was a much weaker Chinese growth level this year, of 4.9% because of supply chain issues. 
Via Talk Markets
More Chinese Trouble
A day after the consumer price rise there was another price rise for producer markets. 
Via Talk Markets
Friday Market Coverage
New hiring again failed to rise in Sept., the 2nd month in a row which may be good news because it could delay the Fed tapering. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
10 Health Care Stocks With Unusual Options Alerts In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option... 
Via Benzinga
< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.